Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001127602-21-024768
Filing Date
2021-09-02
Accepted
2021-09-02 16:23:59
Documents
2
Period of Report
2021-09-01

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form3.html 3  
1 PRIMARY DOCUMENT form3.xml 3 1420
2 POWER OF ATTORNEY (PUBLIC): EXHIBIT 24 - POWER OF ATTORNEY doc1.txt EX-24 3899
  Complete submission text file 0001127602-21-024768.txt   6747
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Issuer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O BIOCRYST PHARMACEUTICALS, INC. 4505 EMPEROR BLVD, SUITE 200 DURHAM NC 27703
Business Address
Galson Steven K (Reporting) CIK: 0001495328 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-23186 | Film No.: 211233542